197 related articles for article (PubMed ID: 32408169)
21. Impaired motor skill learning and altered seizure susceptibility in mice with loss or gain of function of the Kcnt1 gene encoding Slack (K
Quraishi IH; Mercier MR; McClure H; Couture RL; Schwartz ML; Lukowski R; Ruth P; Kaczmarek LK
Sci Rep; 2020 Feb; 10(1):3213. PubMed ID: 32081855
[TBL] [Abstract][Full Text] [Related]
22. Quinidine therapy for West syndrome with KCNTI mutation: A case report.
Fukuoka M; Kuki I; Kawawaki H; Okazaki S; Kim K; Hattori Y; Tsuji H; Nukui M; Inoue T; Yoshida Y; Uda T; Kimura S; Mogami Y; Suzuki Y; Okamoto N; Saitsu H; Matsumoto N
Brain Dev; 2017 Jan; 39(1):80-83. PubMed ID: 27578169
[TBL] [Abstract][Full Text] [Related]
23. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine.
Milligan CJ; Li M; Gazina EV; Heron SE; Nair U; Trager C; Reid CA; Venkat A; Younkin DP; Dlugos DJ; Petrovski S; Goldstein DB; Dibbens LM; Scheffer IE; Berkovic SF; Petrou S
Ann Neurol; 2014 Apr; 75(4):581-90. PubMed ID: 24591078
[TBL] [Abstract][Full Text] [Related]
24. Lack of response to quinidine in KCNT1-related neonatal epilepsy.
Numis AL; Nair U; Datta AN; Sands TT; Oldham MS; Patel A; Li M; Gazina E; Petrou S; Cilio MR
Epilepsia; 2018 Oct; 59(10):1889-1898. PubMed ID: 30182418
[TBL] [Abstract][Full Text] [Related]
25. Characterization of two de novoKCNT1 mutations in children with malignant migrating partial seizures in infancy.
Rizzo F; Ambrosino P; Guacci A; Chetta M; Marchese G; Rocco T; Soldovieri MV; Manocchio L; Mosca I; Casara G; Vecchi M; Taglialatela M; Coppola G; Weisz A
Mol Cell Neurosci; 2016 Apr; 72():54-63. PubMed ID: 26784557
[TBL] [Abstract][Full Text] [Related]
26. Approaches for the discovery of drugs that target K Na 1.1 channels in KCNT1-associated epilepsy.
Miziak B; Czuczwar SJ
Expert Opin Drug Discov; 2022 Dec; 17(12):1313-1328. PubMed ID: 36408599
[TBL] [Abstract][Full Text] [Related]
27. Two South Indian Children with KCNT1-Related Malignant Migrating Focal Seizures of Infancy - Clinical Characteristics and Outcome of Targeted Treatment with Quinidine.
Patil AA; Vinayan KP; Roy AG
Ann Indian Acad Neurol; 2019; 22(3):311-315. PubMed ID: 31359944
[No Abstract] [Full Text] [Related]
28. KCNT1 mutations in seizure disorders: the phenotypic spectrum and functional effects.
Lim CX; Ricos MG; Dibbens LM; Heron SE
J Med Genet; 2016 Apr; 53(4):217-25. PubMed ID: 26740507
[TBL] [Abstract][Full Text] [Related]
29. Functional evaluation of epilepsy-associated KCNT1 variants in multiple cellular systems reveals a predominant gain of function impact on channel properties.
Hinckley CA; Zhu Z; Chu JH; Gubbels C; Danker T; Cherry JJ; Whelan CD; Engle SJ; Nguyen V
Epilepsia; 2023 Aug; 64(8):2126-2136. PubMed ID: 37177976
[TBL] [Abstract][Full Text] [Related]
30. Does age affect response to quinidine in patients with KCNT1 mutations? Report of three new cases and review of the literature.
Abdelnour E; Gallentine W; McDonald M; Sachdev M; Jiang YH; Mikati MA
Seizure; 2018 Feb; 55():1-3. PubMed ID: 29291456
[TBL] [Abstract][Full Text] [Related]
31. Increased Expression of K
Liu R; Sun L; Shi X; Li C; Guo X; Wang Y; Wang X; Zhang K; Wang Y; Wang Q; Wu J
Neurochem Res; 2024 Feb; 49(2):427-440. PubMed ID: 37875713
[TBL] [Abstract][Full Text] [Related]
32. Concurrent Quinidine and Phenobarbital in the Treatment of a Patient with 2
Passey CC; Erramouspe J; Castellanos P; O'Donnell EC; Denton DM
Curr Ther Res Clin Exp; 2019; 90():106-108. PubMed ID: 31388363
[TBL] [Abstract][Full Text] [Related]
33. Coupling of Slack and Na
Yuan T; Wang Y; Jin Y; Yang H; Xu S; Zhang H; Chen Q; Li N; Ma X; Song H; Peng C; Geng Z; Dong J; Duan G; Sun Q; Yang Y; Yang F; Huang Z
Elife; 2024 Jan; 12():. PubMed ID: 38289338
[TBL] [Abstract][Full Text] [Related]
34. Functional Effects of Epilepsy Associated
Rychkov GY; Shaukat Z; Lim CX; Hussain R; Roberts BJ; Bonardi CM; Rubboli G; Meaney BF; Whitney R; Møller RS; Ricos MG; Dibbens LM
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499459
[TBL] [Abstract][Full Text] [Related]
35. An ALS-Associated Mutant SOD1 Rapidly Suppresses KCNT1 (Slack) Na
Zhang Y; Ni W; Horwich AL; Kaczmarek LK
J Neurosci; 2017 Feb; 37(8):2258-2265. PubMed ID: 28119399
[TBL] [Abstract][Full Text] [Related]
36. Quinidine Therapy for Lennox-Gastaut Syndrome With
Jia Y; Lin Y; Li J; Li M; Zhang Y; Hou Y; Liu A; Zhang L; Li L; Xiang P; Ye J; Huang Z; Wang Y
Front Neurol; 2019; 10():64. PubMed ID: 30804880
[TBL] [Abstract][Full Text] [Related]
37. The Phe932Ile mutation in KCNT1 channels associated with severe epilepsy, delayed myelination and leukoencephalopathy produces a loss-of-function channel phenotype.
Evely KM; Pryce KD; Bhattacharjee A
Neuroscience; 2017 May; 351():65-70. PubMed ID: 28366665
[TBL] [Abstract][Full Text] [Related]
38. Precision therapy with quinidine of KCNT1-related epileptic disorders: A systematic review.
Xu D; Chen S; Yang J; Wang X; Fang Z; Li M
Br J Clin Pharmacol; 2022 Dec; 88(12):5096-5112. PubMed ID: 35940594
[TBL] [Abstract][Full Text] [Related]
39. Precision therapy for epilepsy due to
Mullen SA; Carney PW; Roten A; Ching M; Lightfoot PA; Churilov L; Nair U; Li M; Berkovic SF; Petrou S; Scheffer IE
Neurology; 2018 Jan; 90(1):e67-e72. PubMed ID: 29196578
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and biological evaluation of a novel series of 1,2,4-oxadiazole inhibitors of SLACK potassium channels: Identification of in vitro tool VU0935685.
Qunies AM; Spitznagel BD; Du Y; David Weaver C; Emmitte KA
Bioorg Med Chem; 2023 Nov; 95():117487. PubMed ID: 37812884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
